JATENZO
PeakNDAORALCAPSULE
Approved
Mar 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
5/8 — Partial
Drug data last refreshed 37m ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JATENZO is an oral testosterone replacement therapy indicated for men with hypogonadism, delivered as a capsule formulation of testosterone undecanoate. It is the first and only oral testosterone undecanoate product approved in the United States, providing a non-injectable alternative for testosterone supplementation. The drug works by replacing deficient endogenous testosterone levels in hypogonadal men.
$5MPart D
Peak12.4 years to LOEProduct is at peak lifecycle stage with modest Medicare Part D penetration (~4,559 claims in 2023), indicating established presence but constrained market adoption requiring focused commercial strategy.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO® for 12 Months
Started Jul 2024
116 enrolled
Hypogonadism
Career Relevance
JATENZO offers limited immediate career opportunities (0 linked jobs), suggesting a mature, stable product with a lean team structure at Tolmar. Roles available would focus on defending market position and managing reimbursement in a competitive TRT market rather than driving growth initiatives.
Brand Manager
Worked on JATENZO at Tolmar? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.